← Oncology Approval Tracker

FDA DECISION ·

Krazati

adagrasib · Mirati Therapeutics

Accelerated approvalNew therapyNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with locally advanced or metastatic NSCLC harboring KRAS G12C on an FDA-approved test after at least one previous systemic therapy.

LAMPGEN ANALYSIS

Why it matters

The approval adds a targeted treatment option for previously treated KRAS G12C-positive NSCLC.

What research teams should watch

Capture the precise KRAS variant and systemic treatment history. Coordinate medication interaction review and adherence follow-up.

PRIMARY RECORDS

Sources